Andrew Mok

Joel put enterprise operating income up about 5% and pointed to elevated cost per treatment and G&A growth as offsets to the treatment gains, but did not fully bridge the flat U.S. Dialysis line.

Javier declined to characterize industry volumes, attributing DaVita's growth to clinical outcomes and mortality improvement rather than share gains.

CEO noted Fresenius closures involve small centers where Fresenius will try to retain patients in their network. DaVita is making sure the market knows about share availability and physician access. Patients and physicians ultimately choose.

CFO acknowledged mortality improved but said changes are small and not yet a significant trend. CEO added that there are multiple small variables (seasonality, mortality, admissions, missed treatments, transfers) and the raised volume range handicaps all of them.

CEO confirmed $40M year 1, $70M year 2, $10M year 3 phasing. Open enrollment was more resilient than expected but payment yield is unknown. ESKD patients are sophisticated about insurance needs and more likely to retain coverage; CKD patients who lose coverage create a delayed impact as they eventually enter as Medicare.

CFO noted Q4 missed treatments were elevated but consistent with Q4 2024 on a year-over-year basis. Clinical team sees correlation between missed treatment rate and mortality with some lag.

CFO translated the 75-100bps headwind removal to 50-75bps structural YoY improvement after accounting for day mix headwind. CEO walked through the bridge: starting from -100bps in 2025, improving by 50-75bps yields an adjusted starting point of -25 to -50bps.

CEO confirmed $120M cumulative estimate unchanged, phased ~$40M year 1, ~$70M year 2, ~$10M year 3. Explained lumpiness: existing ESKD patients likely retain coverage; CKD patients who lose coverage would enter as Medicare when kidneys fail, creating a delayed payer mix impact.

Lower volume was due to reduced scripts from adherence issues, patients getting binders through other means, and reliance on over-the-counter solutions. Not a mix issue.

CFO explained the missed treatment spike in April/May drove the revision. Changed back-half assumption to flat vs 2024 rather than declining. Entire 25-50bps volume revision is about higher missed treatments.

CEO noted higher-than-expected iron-based binder prescriptions drove mix to upper end. Physicians appear satisfied with current mix based on conversations.

CFO separated costs into two buckets: direct costs will be non-GAAPed and likely insured; indirect costs flow through P&L and are included in guidance.

CFO broke down the 50bps revision: flu census decline was slightly more than half, with the remainder split roughly equally between mistreatment rate and ~500 lost cyber-related admissions.

CFO clarified the per-Medicare-patient amount is $10-$15, with the blended RPT impact of $7.80 reflecting that not all patients are eligible or take the medication.

CEO explained G&A is roughly half traditional inflationary costs and half investment portfolio (IT, revenue operations) that drives benefits on other cost and revenue lines.

Filton enumerated four drivers: new bed capacity, Cedar Hill improvement, moderating behavioral labor costs, and easier Nevada comparisons.

Filton confirmed flu and weather concentrated in January-February. March volumes showed more normative YoY increase as seasonal headwinds cleared, supporting back-half acceleration expectations.

Filton explained headcount is adequate but requires shifting to more RNs. 2026 includes one-time startup costs (recruiting, training, potential short-term volume disruption) that won't repeat. Once fully staffed, ongoing annual cost approximately $30M versus $35M partial-year 2026 impact.

Filton confirmed the bridge: +$185M new DPP revenues, -$50M Cedar Hill drag, and a further offset from scaled-back behavioral volume projections.

Filton admitted they were too optimistic on certification timing. Joint Commission survey expected imminently. $25M drag in Q2, another $25M in H2. Expects facility on track to divisional profitability by 2026.

Filton confirmed no structural changes in referral patterns. Volume weakness attributed solely to weather impacts on outpatient and child/adolescent populations.

Filton said ~75% of purchases insulated from tariffs. Rejecting vendor attempts to add fees on fixed contracts. Monitoring for product availability issues but no significant pressure yet.

Filton attributed the wider range to uncertainty around government reimbursement changes, acknowledging conservatism in guidance.

Filton explained growth is driven by core volume/pricing recovery to historical norms plus malpractice reserve non-recurrence and interest expense reduction.

London stated the margin-first priority but said it was too early in the pricing process, deferring competitive positioning and market growth detail to the Q3 call.

Sarah explained eAPTC expiry drove Silver-to-Bronze shift market-wide, concentrating higher acuity members in Silver. Centene's intentional decision not to pursue aggressive bronze strategy retained more Silver members. Risk adjustment mechanism specifically designed to counteract adverse selection. Full risk adjustment range wraps around original 4% target and higher at top end, but guidance only reflects partial offset at 3% pretax pending June Wakely.

Drew clarified MA HBR actually expected to improve in 2026. The apparent Medicare segment pressure is mathematical: PDP margin stepping from 3%+ to 2% plus direct subsidy increase from $143 to $200 driving higher premium and pharmacy expense with zero incremental admin, creating mechanical HBR increase within the 35bps segment impact on consolidated HBR.

Sarah clarified the flat Medicaid profitability assumption reflects prudence given limited 1/1 rate visibility and elevated trend, not changed conviction. Starting from better-than-expected trajectory of 93.7% full year.

Sarah confirmed pricing to return marketplace to profitability in 2026 but said too early to specify target margin range. View gets clearer after rate filings, state certifications in August, and landscape file in September.

Drew explained risk corridor triggers at 2.5% above bid assumption with 50/50 split. Making up in SG&A to still hit 1% pretax margin. Cannot assume same corridor level in 2026 bids.

Sarah confirmed 20-30% is without major mitigation. Team has run numerous scenarios on caps, buydowns, and product design across FPL continuum, including potentially filing two sets of bids.

Prem attributed 340B pressure to manufacturer restrictions on covered entities and specialty-to-generic conversion; Brian declined to size the headwind, deferring to the Q3 and Q4 calls.

Management described AI as transformative and strategic across enterprise but did not quantify investment levels or provide specific P&L inflection timeline; share repo not in 2026 guide but evaluating.

Nelson attributed growth to better-than-expected retention and innovative products resonating with sophisticated purchasers. Fully insured pressured by pricing discipline but offset by self-funded growth.

Newman declined to share pretax loss but confirmed impairment driven by slowed clinic growth. Shah outlined four focus areas but would not comment on specific payer contracts.

Newman explained different populations and that Aetna members are still minority of Oak Street patients. Shah outlined four focus areas: leadership, technology, clinical solutions, thoughtful expansion.

Shah acknowledged Oak Street pressure but called it very immature and offset by favorability elsewhere in healthcare delivery. Did not directly address D-SNP year two operational question.

Cowhey detailed IFP membership expected to shrink from 1.85M to sub-1M. Nelson highlighted geographic/product mix changes and improved risk adjustment capabilities.

Mark explained ~$0.50 operating outperformance split between MA and ACA and framed non-extrapolation as prudence for the second half.

Morgan discussed employer alignment with affordability strategy and fee-based funding shift but did not directly address gas prices or macro impact on utilization. Mark noted ACA bronze shift in line with expectations.

Felicia confirmed membership high teens decline but consistent with deliberate strategy. Attrition concentrated in PPO and unmatched HMO geographies. Positioned to deliver Medicare margin at least 2% in 2026. Mark added employer group risk declining high single-digit percent from deliberate pricing on sub-threshold margin accounts.

Mark provided comprehensive segment-level update: Medicaid below breakeven, ACA margins declining high single-digit percent but some favorability, Medicare margins slightly improving supported by retention and cost management, commercial group consistent with expectations.

Mark decomposed ACA pressure: 70% from risk pool acuity/morbidity shift, 30% from utilization including ER visits, behavioral health, and aggressive IDR/coding practices.

Mark attributed the BER variance to a Medicaid state premium tax that reduced BER but increased OpEx with no material impact on operating earnings. Plus Part D IRA seasonality.

Felicia confirmed strong AEP driven by a large group MA conversion. Gail clarified minimal additional growth expected rest of year beyond strong retention.

Marks explicitly stated 21 months of benefit booked in the quarter, explained the accrual rationale and noted cash was being received against the approval in July.

Mike attributed slowdown to immigration-related concerns reducing willingness to file applications. Did not specify states. Said it's too early to call sustained vs temporary.

Mike broke out outpatient surgery: hospitals flat, ASCs down ~1.5%. Payer mix soft driven by Medicaid decline. Lower-intensity cases like ENT declining. Sam noted ~100 outpatient units added in 2025, pipeline accelerating for 2026-27.

Sam confirmed one of two underperforming divisions recovered in Q3. Second still working through challenges but confident in 2026 recovery. Portfolio diversification absorbs individual division weakness.

Mike detailed hurricane recovery: $100M better than flat guidance. Largo earnings growing YoY, NC still negative in Q2 with recovery expected Q4. Sam noted NC seeing greater demand but tighter labor requiring more contract labor.

Mike clarified that Largo improvement and North Carolina lingering effects offset each other as guided, producing flat year-over-year earnings in hurricane markets.

Mike detailed volume drags from respiratory season (1pt admissions, 2pt ER visits) and hurricanes (20-40 bps). Confirmed Largo and NC expected to offset in 2025 guidance.